Currently, up to 9% of American adults suffer from chronic asthma*, and in 60% of these cases the asthma is attributable to allergy. 

In the United States alone, the number of people diagnosed with allergy will increase by more than a million a year by 2060.

Although this growing disease already affects nearly one adult in 20, there is no cure or treatment for allergic asthma. And it’s no different for the allergy that causes it. The only solutions available for allergic asthma sufferers are symptomatic remedies or demanding desensitization treatments. Both approaches have shown their limits. Patients and their families are looking for something better. The unmet need is truly considerable.

It’s for them that ANGANY is developing a totally new approach. It involves treating allergic asthma by reversing the underlying immune dynamics, restoring immune tolerance to the allergen in question.

The new-generation biologics under development at ANGANY offer the prospect of previously unattainable safety and efficacy attributes in the treatment of allergic asthma. Affected individuals can now look forward to a new therapeutic solution that will enable them to develop a protective response against the precise cause of their allergy, and thus control allergic asthma.

Both genetic and external factors can promote an allergic response against a component, usually a protein, from a source such as pollen or cat glands. ANGANY’s approach is to present the specific component to be treated as a 3D structure that the immune system perceives as a threat. This redirects the immune response towards one of a protective nature, promoting the gradual elimination of the programmed allergic response.